Aytu Biopharma Inc. Stock
€2.58
Your prediction
Aytu Biopharma Inc. Stock
Pros and Cons of Aytu Biopharma Inc. in the next few years
Pros
Cons
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.In reviewing the financial documents, it is clear from the outset that Aytu Biopharma's financial metrics depict a complex and nontrivial picture - a textbook case for both investors and market spectators. On the surface, this biopharma company has certainly experienced its fair share of challenges, compounded by tricky performances from several of its financial metrics.
One positive aspect of ABiopharma's financial health can be seen in their Revenue Per Share. The company holds a Revenue Per Share TTM (Trailing Twelve Months) of 32.156, which represents a robust earning capacity per share. This metric demonstrates that Aytu's profits made from its operations are distributed across each outstanding share of its common stock.
Indeed, when assessing their Gross Profit, we note it reaches a substantial number, standing at 66,632,000. Gross profit is an integral catalyst to any company's financial wellbeing - it seriously affects the firm's profitability and overall net income. Essentially, the higher the gross profit margin, the more capital the company retains on each dollar of sales.
Comments
